# GPT 5.2 Review - Reviewer 1/3 (Parallel)

**Model:** gpt-5.2-2025-12-11
**Paper:** paper.pdf
**Reasoning effort:** medium
**Timestamp:** 2026-01-21T16:28:59.818401
**Review mode:** Parallel (3 independent reviewers)
**Response ID:** resp_073b63be693ddf94006970f01bbbb481969255ea5d0a5c4d76
**Tokens:** 10055 in / 5194 out
**Response SHA256:** cc3f4f5b8ac58558

---

## Referee Report: “Do State Insulin Price Caps Improve Diabetes Management? Evidence from Staggered Policy Adoption” (January 2026)

### Summary
The paper asks an important and policy-relevant question: whether state insulin out-of-pocket caps improve diabetes management (insulin use, A1C monitoring, etc.). The author uses BRFSS 2019–2022 and a staggered DiD design with Callaway–Sant’Anna (CS) and Sun–Abraham event studies. The headline result is a small, imprecise increase in insulin use (~1.9pp, SE 1.3pp) with event-study patterns that show statistically significant *pre-trends*, undermining credibility.

For a top general-interest journal or AEJ:EP, the current draft is **not close**. The core empirical design is underpowered, the key identifying assumption is directly challenged by the author’s own pre-trend estimates, treatment timing is misaligned with annual BRFSS measurement, the unit of analysis (state-year aggregates) discards most of the microdata variation, and inference/reporting fall well short of top-journal standards.

---

# 1. FORMAT CHECK

### Length
- **Fails** top-journal expectations. The PDF content shown runs to roughly **17 pages** including appendix material/figures (page numbers visible up to 17). Excluding references/appendix, the main text appears closer to ~13–15 pages. Top journals typically expect **25+ pages** of main text (excluding refs/appendix), and more importantly a substantially deeper empirical and institutional analysis.

### References
- **Inadequate** for a top field/general journal. Only ~7 references are listed, and several citations are placeholders (“(?)”, “??”) throughout the text (e.g., Introduction and Institutional Background). This is a major issue.

### Prose vs bullets
- The paper is mostly in paragraph form. Bullet lists are used for outcome definitions (Section 3.1), which is acceptable.
- However, there are several “list-like” passages and repeated short paragraphs that read like a technical memo rather than a journal article.

### Section depth (3+ substantive paragraphs each)
- **Introduction**: yes (multiple paragraphs).
- **Institutional Background**: yes.
- **Data**: borderline—definitions are fine, but the aggregation decision needs a *much* more developed defense and consequences for inference/power.
- **Empirical Strategy**: yes, but missing key details on implementation choices (micro vs aggregate, weights, exposure timing).
- **Results/Discussion**: present, but too thin for a top journal given identification concerns.

### Figures
- Figures have visible data and axes, but are **not publication quality**:
  - Event-study figure needs clearer axis scaling, explicit sample/cohort inclusion, and a note on omitted bins and exposure definition.
  - The cohort trend figure (Figure 1) is suggestive but not a substitute for credible pre-trend diagnostics (and your formal event study contradicts it).

### Tables
- Tables shown contain real numbers (no placeholders), which is good.
- But the regression table is far from top-journal standards (missing N by specification, missing p-values, unclear clustering, unclear weighting, unclear estimand).

---

# 2. STATISTICAL METHODOLOGY (CRITICAL)

### a) Standard Errors
- **Partial pass**: Main effects in Table 3 report SEs in parentheses, and clustering at the state level is stated.
- But many reported quantities (event-study coefficients in Figure 2; placebo; leave-one-out) are described without a consistent tabular reporting of coefficients+SEs.

### b) Significance testing (p-values / t-stats / stars)
- **Fail by top-journal standards**: The paper often states “statistically significant” but does not report **p-values**, **t-stats**, or conventional significance notation in tables.
- Top journals do not *require* stars, but they do require complete inference reporting. Here it is inconsistent and incomplete.

### c) Confidence intervals
- **Partial pass**: Table 3 provides 95% CIs for the CS ATT. That is good.
- But CIs should be shown (or at least available in appendix tables) for all key outcomes and dynamic effects, not only one coefficient.

### d) Sample sizes
- **Fail**: N is not reported in a regression-ready way.
  - The draft mentions “States 54” and “State-years 78–212” (Table 3), which is confusing and unacceptable. Each table/specification should clearly report:
    - number of states,
    - number of state-years used in that regression,
    - number of treated states contributing to each event-time coefficient,
    - (if microdata used) number of individual observations and effective sample sizes with weights.

### e) DiD with staggered adoption
- **Conceptual pass**: The author correctly cites TWFE problems and uses CS and Sun–Abraham.
- **However**: the implementation raises serious concerns:
  1. **Aggregation to state-year**: CS is typically implemented on microdata or at least on repeated cross-sections with rich unit-level variation. Collapsing to **~200 observations** (54×4 minus missing) sacrifices power and makes inference extremely fragile.
  2. **Small number of clusters** (≈54): cluster-robust SEs may be unreliable; should use **wild cluster bootstrap** or randomization inference.
  3. **Treatment timing with annual data**: Texas is effective Sept 2021; coding the entire 2021 as treated (or even partially treated without modeling exposure) creates misclassification attenuation and spurious dynamics.

### f) RDD
- Not applicable.

**Bottom line on methodology:** even though the paper uses “modern DiD” estimators, **inference and reporting are below the publishability threshold** for the target journals, and the aggregation/timing choices likely drive the imprecision and questionable dynamics. As written, the paper is not publishable.

---

# 3. IDENTIFICATION STRATEGY

### Credibility
- The identification is **not currently credible** because the paper’s own event study shows **statistically significant pre-treatment coefficients** (Figure 2 and Section 5.2). This is a first-order problem: it indicates violation of parallel trends or non-comparability of treated vs control states.

### Assumptions discussed
- Parallel trends is discussed in Section 4, which is good.
- But the paper does not adequately explore *why* pre-trends appear, nor does it provide a credible fix.

### Placebos/robustness
- There is a placebo and leave-one-out exercise, but they do not address the key threats:
  - **Endogenous policy adoption** (states enact caps amid changing diabetes management, insurance market reforms, Medicaid policy changes, etc.).
  - **Differential COVID shocks** (2020–2022 are dominated by pandemic disruptions).
  - **Non-coverage of ERISA self-insured plans** (a huge share of privately insured), implying weak first stage and heterogeneous exposure by state.
  - **Treatment mismeasurement** (cap effective dates, implementation lags, enforcement, and insurer compliance).

### Conclusions vs evidence
- The paper appropriately caveats interpretation, but still occasionally slips into policy interpretation that reads too strong given identification failure (e.g., “suggest either no effect or modest positive effect…”). With significant pre-trends, the safest conclusion is: **“BRFSS + this DiD design cannot identify the causal effect.”**

### Limitations
- Limitations are acknowledged (short post period, COVID, wrong margin), which is good.
- But the most important limitation—**parallel trends violation**—is not addressed with adequate alternative designs or sensitivity analysis.

---

# 4. LITERATURE (Missing references + BibTeX)

## Methodology literature missing (high priority)
You cite CS (2021), Goodman-Bacon (2021), Sun–Abraham (2021). For a top journal, you must also engage:

1) **Borusyak, Jaravel & Spiess (event-study estimation and imputation approach)**  
Relevance: provides a robust alternative implementation and clarifies weighting/pathologies; useful given your dynamic estimates and short panels.
```bibtex
@techreport{BorusyakJaravelSpiess2021,
  author = {Borusyak, Kirill and Jaravel, Xavier and Spiess, Jann},
  title = {Revisiting Event Study Designs: Robust and Efficient Estimation},
  institution = {National Bureau of Economic Research},
  type = {Working Paper},
  number = {28364},
  year = {2021}
}
```

2) **de Chaisemartin & D’Haultfoeuille (TWFE pathologies; robust alternatives)**  
Relevance: canonical critique and alternative estimands/estimators under staggered adoption.
```bibtex
@article{deChaisemartinDHaultfoeuille2020,
  author = {de Chaisemartin, Cl{\'e}ment and d'Haultfoeuille, Xavier},
  title = {Two-Way Fixed Effects Estimators with Heterogeneous Treatment Effects},
  journal = {American Economic Review},
  year = {2020},
  volume = {110},
  number = {9},
  pages = {2964--2996}
}
```

3) **Rambachan & Roth (“Honest DiD” / sensitivity to trend violations)**  
Relevance: your pre-trends are significant; you need formal sensitivity analysis rather than informal discussion.
```bibtex
@techreport{RambachanRoth2022,
  author = {Rambachan, Ashesh and Roth, Jonathan},
  title = {A More Credible Approach to Parallel Trends},
  institution = {National Bureau of Economic Research},
  type = {Working Paper},
  number = {25512},
  year = {2022}
}
```

4) **Inference with few clusters / wild cluster bootstrap**  
Relevance: you have ~54 clusters and very short T; standard CRSE may be misleading.
```bibtex
@article{CameronGelbachMiller2008,
  author = {Cameron, A. Colin and Gelbach, Jonah B. and Miller, Douglas L.},
  title = {Bootstrap-Based Improvements for Inference with Clustered Errors},
  journal = {Review of Economics and Statistics},
  year = {2008},
  volume = {90},
  number = {3},
  pages = {414--427}
}
```

## Policy/domain literature missing (high priority)
The insulin affordability crisis and policy responses have a large medical/policy literature. At minimum, you should cite empirical work on:
- insulin rationing and outcomes (beyond Herkert et al. 2019),
- cost-sharing caps and adherence,
- ACA/Medicaid/market reforms affecting diabetes care,
- prior evaluations of insulin caps using claims (you cite a “Texas A&M Health (2024)” non-peer-reviewed style reference; top journals will require the underlying working paper / peer-reviewed paper).

Because your draft currently uses placeholders (“(?)”) for core factual claims (tripling prices; rationing prevalence; prior cap spending effects), the literature section is not credible as written.

---

# 5. WRITING QUALITY (CRITICAL)

### a) Prose vs bullets
- Generally acceptable on bullets, but the writing reads like a policy report rather than an AER/QJE/JPE paper. Key arguments are asserted quickly, without the depth and careful sequencing expected.

### b) Narrative flow
- Motivation is strong and timely.
- But the “arc” breaks when the paper reaches results: the reader immediately sees pre-trend violations, and the paper does not offer a coherent plan for what can still be learned despite that (e.g., alternative estimands, sensitivity bounds, subpopulations with stronger first stage).

### c) Sentence quality
- Serviceable but repetitive and sometimes imprecise (e.g., “small, imprecise overall treatment effect” repeated in multiple places).
- Several statements are too hand-wavy for a top journal (“not obviously responses to particularly acute affordability crises”; this needs evidence).

### d) Accessibility
- Econometric choices are explained at a high level; that’s good.
- Magnitudes are not sufficiently contextualized. For instance: what does a 1.9pp increase in “any insulin use among all diabetics” mean clinically/policy-wise, given a large share will never need insulin?

### e) Figures/Tables
- Not publication quality yet (labels, cohort composition, treatment timing/exposure, and notes are insufficient).
- Tables need complete inference reporting and consistent N.

**Writing verdict:** not yet at the level expected for general-interest outlets. A rewrite is needed once the identification strategy is repaired.

---

# 6. CONSTRUCTIVE SUGGESTIONS (How to make this publishable)

## A. Fix the core data/estimand mismatch
1) **Do not aggregate to state-year means** as the primary analysis. Use individual BRFSS microdata (repeated cross-section DiD) with:
   - state FE, year FE,
   - appropriate survey weights,
   - clustering at the state level (with wild bootstrap / randomization inference).
   Aggregation to 200 observations is an own-goal for power and inference.

2) **Redefine the estimand to match who is affected.** Price caps primarily affect:
   - privately insured in **fully insured** plans regulated by the state,
   - some state employee plans / some Medicaid MCOs (varies by state).
   BRFSS includes insurance status—use it:
   - insured vs uninsured,
   - private vs Medicaid vs Medicare,
   - (if available) employer-sponsored vs individual market proxies.
   A **triple-difference** comparing privately insured vs Medicare/uninsured across treated vs untreated states over time would be far more compelling.

## B. Repair identification (pre-trends)
Given significant pre-trends, you need one (or more) of:
1) **State-specific linear trends** *with caution* (and discuss why this is not a mechanical fix).
2) **Matching / synthetic control style reweighting** to construct comparable controls (e.g., generalized synthetic control, augmented SCM) and show robustness.
3) **Honest DiD / sensitivity bounds** (Rambachan–Roth) to quantify how large deviations from parallel trends must be to overturn conclusions.
4) **Border-county design** (if you can obtain county identifiers in BRFSS restricted files, or use other data): compare counties near borders of adopting vs non-adopting states.

## C. Correct treatment timing and exposure
- Annual BRFSS measurement cannot cleanly capture policies effective mid-year. At minimum:
  - code treatment as active only when effective for a full year (e.g., Texas treated starting 2022, not 2021),
  - or use fractional exposure in year-of-adoption,
  - and run robustness to alternative coding.
- Also: **2023 adopters are not treated in 2019–2022**. They should not be “eventually treated” in descriptive “treated vs never” comparisons unless you are explicit that they are controls in the estimation window.

## D. Strengthen outcomes (move beyond “any insulin use”)
“Are you taking insulin?” is a very blunt outcome. Better outcomes (likely requiring claims/EHR):
- days supply / fills / adherence (PDC/MPR),
- insulin rationing proxies (early refill gaps),
- A1C levels (not just “checked”),
- ER visits/hospitalizations for DKA/hyperglycemia,
- complications.

If you must stay in BRFSS:
- focus on subgroups more likely to be on insulin (e.g., long-duration diabetes, insulin-dependent, poor health, younger Type 1 proxies),
- explore outcomes more responsive to affordability (skipping care due to cost; BRFSS has cost-barrier questions).

## E. Inference and presentation upgrades
- Report p-values (or stars) systematically.
- Provide a full event-study coefficient table with Ns by event time.
- Use wild cluster bootstrap p-values as a robustness check.
- Pre-register (or at least pre-specify) the main outcome and design choices to reduce specification searching concerns.

---

# 7. OVERALL ASSESSMENT

### Key strengths
- Important policy question with clear motivation (Intro).
- Correct awareness of staggered DiD pitfalls; attempts CS and Sun–Abraham rather than naive TWFE.
- Transparent discussion of limitations (COVID, short post window, outcome coarseness).

### Critical weaknesses (must-fix)
1) **Parallel trends failure** (significant pre-trends) makes the main causal claim not identified.
2) **Unit-of-analysis choice (state-year aggregation)** severely reduces power and undermines inference.
3) **Treatment timing/exposure mismeasurement** with annual BRFSS and mid-year effective dates.
4) **Inference/reporting incomplete** (no p-values, unclear N, inconsistent reporting across exercises).
5) **Literature is far too thin** and contains placeholders, which is a nonstarter for a top journal.

### Specific path to a credible revision
A credible resubmission would (i) use micro BRFSS, (ii) move to a DDD strategy by insurance type / likely exposure, (iii) correct treatment timing, (iv) use honest/sensitivity methods for pre-trends, and (v) ideally validate first-stage spending reductions using claims (or at least external evidence) to show the policy actually changes OOP costs for the analyzed population in each state.

---

DECISION: REJECT AND RESUBMIT